Control of osteopontin signaling and function by post-translational phosphorylation and protein folding

Journal of Cellular Biochemistry

Volumn 102, Issue 4, 2007, Pages 912-924

  Kazanecki, Christian C ^a   Uzwiak, Dana J ^a   Denhardt, David T ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b Department of Molecular Biology and Biochemistry   (United States)

Author keywords

Apoptosis; Beta sheet; CD44; Integrins; Phosphorylation

Indexed keywords

CD44V ANTIGEN; INTEGRIN; OSTEOPONTIN; SERINE;

APOPTOSIS; BETA SHEET; CELL TYPE; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; REVIEW;

ANIMALS; HUMANS; OLIGOPEPTIDES; OSTEOPONTIN; PHOSPHORYLATION; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 35648934023     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21558     Document Type: Review

References (89)

1. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. 2001. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 276:28261-28267.
2. Andrew CD, Warwicker J, Jones GR, Doig AJ. 2002. Effect of phosphorylation on alpha-helix stability as a function of position. Biochemistry 41:1897-1905.
3. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H. 2000. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287:860-864.
4. Barry ST, Ludbrook SB, Murrison E, Horgan CM. 2000. Analysis of the alpha4beta1 integrin-osteopontin interaction. Exp Cell Res 258:342-351.
5. Bates PA, Kelley LA, MacCallum RA, Sternberg MJE. 2001. Enhancement of protein modelling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins Struct Funct Genet Suppl 5:39-46.
6. Beshensky AM, Wesson JA, Worcester EM, Sorokina EJ, Snyder CJ, Kleinman JG. 2001. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol 12:2108-2116.
7. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. 2002. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71:145-154.
8. Chellaiah MA, Hruska KA. 2003. The integrin alpha(v)-beta(3) and CD44 regulate the actions of osteopontin on osteoclast motility. Calcif Tissue Int 72:197-205.
9. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA. 2003. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14:173-189.
10. Chiba S, Okamoto H, Kon S, Kimura C, Murakami M, Inobe M, Matsui Y, Sugawara T, Shimizu T, Uede T, Kitabatake A. 2002. Development of atherosclerosis in osteopontin transgenic mice. Heart Vessels 16:111-117.
11. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES. 2005. Post-translationally modified residues of native human osteopontin are located in clusters: Identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285-292.
12. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES. 2007. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem 282:19463-19472.
13. Clamp M, Cuff J, Searle SM, Barton GJ. 2004. The Jalview Java alignment editor. Bioinformatics 20:426-427.
14. Clark RAF, An J-Q, Greiling D, Khan A, Schwarzbauer JE. 2003. Fibroblast migration on fibronectin requires three distinct functional domains. J Invest Dermatol 121:695-705.
15. Crawford HC, Matrisian LM, Liaw L. 1998. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206-5215.
16. Cuff JA, Barton GJ. 2000. Application of multiple sequence alignment profiles to improve protein secondary structure prediction. Proteins 40:502-511.
17. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. 2001. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061.
18. Ek-Rylander B, Flores M, Wendel M, Heinegård D, Andersson G. 1994. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 269:14853-14856.
19. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. 2006. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17:463-474.
20. Fisher LW, Fedarko NS. 2003. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44 (Suppl 1):33-40.
21. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. 2001. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280:460-465.
22. Gao C, Guo H, Downey L, Marroquin C, Wei J, Kuo PC. 2003. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24:1871-1878.
23. Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sørensen ES, Boskey AL. 2005. Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77:45-54.
24. Giachelli CM, Steitz S. 2000. Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol 19:615-622.
25. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. 1998. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 152:353-358.
26. Hoyer JR, Asplin JR, Otvos L. 2001. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77-82.
27. Hu DD, Hoyer JR, Smith JW. 1995a. Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin alpha v beta 3. J Biol Chem 270:9917-9925.
28. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. 1995b. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 270:26232-26238.
29. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. 1996. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 317(Pt 1):59-64.
30. Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M. 2001. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276:13065-13071.
31. Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Noda M. 2002. Resistance to unloading-induced three-dimensional bone loss in osteopontin-deficient mice. J Bone Miner Res 17:661-667.
32. Ito S, Saito T, Amano K. 2004. In vitro apatite induction by osteopontin: Interfacial energy for hydroxyapatite nucleation on osteopontin. J Biomed Mater Res A 69:11-16.
33. Jono S, Peinado C, Giachelli CM. 2000. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275:20197-22203.
34. Kaartinen MT, Murshed M, Karsenty G, McKee MD. 2006. Osteopontin upregulation and polymerization by transglutaminase 2 in calcified arteries of matrix Gla protein-deficient mice. J Histochem Cytochem 55:375-386.
35. Kasugai S, Zhang Q, Overall CM, Wrana JL, Butler WT, Sodek J. 1991. Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter. Bone Miner 13:235-250.
36. Katagiri YU, Sleeman J, Fujii H, Herrlich P, Hotta H, Tanaka K, Chikuma S, Yagita H, Okumura K, Murakami M, Saiki I, Chambers AF, Uede T. 1999. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and Chemotaxis. Cancer Res 59:219-226.
37. Katayama Y, House CM, Udagawa N, Kazama JJ, McFarland RJ, Martin TJ, Findlay DM. 1998. Casein kinase 2 phosphorylation of recombinant rat osteopontin enhances adhesion of osteoclasts but not osteoblasts. J Cell Physiol 176:179-187.
38. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. 2007. Effects of osteopontin defficiency and aging on nanomechanics of mouse bone. J Biomed Materials Res 83:136-144.
39. Kazanecki CC. 2007. Osteopontin and cell adhesion: Role of post-translational modifications and the C-terminal region. Doctoral dissertation, Graduate Program in Microbiology and Molecular Genetics. Rutgers: The State University of New Jersey.
40. Kazanecki CC, Kowalski AJ, Ding T, Rittling SR, Denhardt DT. 2007. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications. J Cell Biochem [Epub ahead of print].
41. Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G. 2005. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990-7003.
42. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. 2002. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85:728-736.
43. Khan SA, Cook AC, Kappil M, Gunthert U, Chambers AF, Tuck AB, Denhardt DT. 2005. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 22:663-673.
44. Konya E, Umekawa T, Iguchi M, Kurita T. 2003. The role of osteopontin on calcium oxalate crystal formation. Eur Urol 43:564-571.
45. Koyama Y, Rittling SR, Tsuji K, Hino K, Salincarnboriboon R, Yano T, Taketani Y, Nifuji A, Denhardt DT, Noda M. 2006. Osteopontin deficiency suppresses high phosphate load-induced bone loss via specific modulation of osteoclasts. Endocrinology 147:3040-3049.
46. Kubota T, Zhang Q, Wrana JL, Ber R, Aubin JE, Butler WT, Sodek J. 1989. Multiple forms of Sppl (secreted phosphoprotein, osteopontin) synthesized by normal and transformed rat bone cell populations: Regulation by TGF-beta. Biochem Biophys Res Commun 162:1453-1459.
47. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. 2007. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67:2089-2097.
48. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. 2000. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275:20959-20962.
49. Marroquin CE, Downey L, Guo H, Kuo PC. 2004. Osteopontin increases CD44 expression and cell adhesion in RAW 264.7 murine leukemia cells. Immunol Lett 95:109-112.
50. Masuda K, Takahashi N, Tsukamoto Y, Honma H, Kohri K. 2000. N-Glycan structures of an osteopontin from human bone. Biochem Biophys Res Commun 268:814-817.
51. McKee MD, Nanci A. 1996. Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: Ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech 33:141-164.
52. McKee MD, Nanci A, Khan SR. 1995. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913-1929.
53. Nagata T, Todescan R, Goldberg HA, Zhang Q, Sodek J. 1989. Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Commun 165:234-240.
54. Nemir M, DeVouge MW, Mukherjee BB. 1989. Normal rat kidney cells secrete both phosphorylated and nonphosphorylated forms of osteopontin showing different physiological properties. J Biol Chem 264:18202-18208.
55. Ohri R, Tung E, Rajachar R, Giachelli CM. 2005. Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcif Tissue Int 76:307-315.
56. O'Regan A, Berman JS. 2000. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 81:373-390.
57. Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK. 2004. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 378:1083.
58. Pollastri G, McLysaght A. 2005. Porter: A new, accurate server for protein secondary structure prediction. Bioinformatics 21:1719-1720.
59. Qin C, Baba O, Butler WT. 2004. Post-translational modifications of SIBLING proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15:126-136.
60. Raghava GPS. 2002. APSSP2 : A combination method for protein secondary structure prediction based on neural network and example based learning. CASP 5:A-132.
61. Rangaswami H, Bulbule A, Kundu GC. 2006. Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol 16:79-87.
62. Razzouk S, Brunn JC, Qin C, Tye CE, Goldberg HA, Butler WT. 2002. Osteopontin posttranslational modifications, possibly phosphorylation, are required for in vitro bone resorption but not osteoclast adhesion. Bone 30:40-47.
63. Rittling SR, Chambers AF. 2004. Role of osteopontin in tumour progression. Br J Cancer 90:1877-1881.
64. Rittling SR, Chen Y, Feng F, Wu Y. 2002. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 277:9175-9182.
65. Rosenthal AK, Gohr CM, Uzuki M, Masuda I. 2007. Osteopontin promotes pathologic mineralization in articular cartilage. Matrix Biol 26:96-105.
66. Safran JB, Butler WT, Farach-Carson MC. 1998. Modulation of osteopontin post-translational state by 1,25-(OH)2-vitaminD3.Dependence on Ca2+ influx. J Biol Chem 273:29935-29941.
67. Salih E, Zhou HY, Glimcher MJ. 1996. Phosphorylation of purified bovine bone sialoprotein and osteopontin by protein kinases. J Biol Chem 271:11905-16897.
68. Samanna V, Wei H, Ego-Osuala D, Chellaiah MA. 2006. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells. Exp Cell Res 312:2214-2230.
69. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB. 1997. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36:5729-5738.
70. Singh M, Ananthula S, Milhorn DM, Krishnaswamy G, Singh K. 2007. Osteopontin: A novel inflammatory mediator of cardiovascular disease. Front Biosci 12:214-221.
71. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R, Jr., Li IW, Kim RH. 1995. Regulation of osteopontin expression in osteoblasts. Ann NY Acad Sci 760:223-241.
72. Sodek J, Ganss B, McKee MD. 2000. Osteopontin. Crit Rev Oral Biol Med 11:279-303.
73. Sørensen ES, Rasmussen LK, Moller L, Jensen PH, Hojrup P, Petersen TE. 1994. Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem J 304(Pt 1):13-16.
74. Sørensen ES, Hojrup P, Petersen TE. 1995. Posttranslational modifications of bovine osteopontin: Identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4:2040-2049.
75. Speer MY, Chien YC, Quan M, Yang HY, Vali H, McKee MD, Giachelli CM. 2005. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 66:324-333.
76. Standal T, Borset M, Sundan A. 2004. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179-184.
77. Suzuki K, Zhu B, Rittling SR, Denhardt DT, Goldberg HA, McCulloch CA, Sodek J. 2002. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 17:1486-1497.
78. Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, Lee NH. 2005. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-Ras V12. Oncogene 24:489-501.
79. Umekawa T, Iguchi M, Kurita T. 2001. The effect of osteopontin immobilized collagen granules in the seed crystal method. Urol Res 29:282-286.
80. Wai PY, Kuo PC. 2004. The role of osteopontin in tumor metastasis. J Surg Res 121:228-241.
81. Wang KW, Shi Y, Denhardt DT. 2007. Osteopontin regulates hindlimb-unloading-induced lymphoid organ atrophy and weight loss by modulating corticosteroid production. Proc Natl Acad Sci 104:14777-14782.
82. Weber GF, Ashkar S, Glimcher MJ, Cantor H. 1996. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509-512.
83. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. 2002. Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 72:752-761.
84. Wu Y, Denhardt DT, Rittling SR. 2000. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156-163.
85. Yasui T, Fujita K, Asai K, Kohri K. 2002. Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells. Int J Urol 9:100-108.
86. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D. 1999. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274:36328-36334.
87. Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. 2005. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 24:418-427.
88. Yoshitake H, Rittling SR, Denhardt DT, Noda M. 1999. Osteopontin- deficient mice are resistant to ovariectomyinduced bone resorption. Proc Natl Acad Sci USA 96:8156-8160.
89. Zohar R, Lee W, Arora P, Cheifetz S, McCulloch C, Sodek J. 1997. Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol 170:88-100.